Immune checkpoint inhibition in classical hodgkin lymphoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan; 69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018 May; 93(5):704–715.
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory hodgkin lymphoma. Semin Hematol. 2016 Jul; 53(3):180–185.
   PubMed Web of Science ®Google Scholar
• Younes A, Ansell S, Fowler N. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017 Jun; 14(6):335–346.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug; 8(8):793–800.
   PubMed Web of Science ®Google Scholar
• Fs H, Sj O, Df M. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct 28; 116(17):3268–3277.
   PubMed Web of Science ®Google Scholar
• Küppers R, Rajewsky K. The origin of hodgkin and reed/sternberg cells in hodgkin’s disease. Annu Rev Immunol. 1998;16(1):471–493.
   PubMedGoogle Scholar
• Dolcetti R, Boiocchi M, Gloghini A. Pathogenetic and histogenetic features of HIV-associated hodgkin’s disease. Eur J Cancer. 2001 Jul; 37(10):1276–1287.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of hodgkin lymphoma. Blood. 2008 Mar 15; 111(6):3220–3224.
   PubMed Web of Science ®Google Scholar
• Harris NL. Hodgkin’s lymphomas: classification, diagnosis, and grading. Semin Hematol. 1999 Jul;36(3):220–232.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Lorenzon D, Cattaruzza L. Expression of CCR5 receptors on reed–sternberg cells and hodgkin lymphoma cell lines: involvement of CCL5/rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 2008;122(4):769–776.
   PubMed Web of Science ®Google Scholar
• Pinto A, Aldinucci D, Gloghini A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a hodgkin’s disease cell line. Blood. 1996 12 01; 88(9):3299–3305.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011 May 10; 29(14):1812–1826.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Owen A. Defining characteristics of classical hodgkin lymphoma microenvironment T-helper cells. Blood. 2013 Oct 17; 122(16):2856–2863.
   PubMed Web of Science ®Google Scholar
• Huang X, Van Den Berg A, Gao Z. Expression of HLA class I and HLA class II by tumor cells in Chinese classical hodgkin lymphoma patients. Plos One. 2010;5(5):e10865.
   PubMed Web of Science ®Google Scholar
• Shan T, Chen S, Wu T. PD-L1 expression in colon cancer and its relationship with clinical prognosis. Int J Clin Exp Pathol. 2019;12(5):1764–1769.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol. 2018 Apr 1; 36(10):942–950.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016 Aug 10; 34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Keir ME, Francisco LM, Sharpe AHPD-1. and its ligands in T-cell immunity. Curr Opin Immunol. 2007 Jun; 19(3):309–314.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013 Jul 1; 19(13):3462–3473.
   PubMed Web of Science ®Google Scholar
• Vari F, Arpon D, Keane C. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809–1819.
   PubMed Web of Science ®Google Scholar
• Vera-Lozada G, Barros MHM, Alves P. EOMES/TBET and soluble CTLA4/full length CTLA4 expression ratios impact on the therapeutic response in patients with classical hodgkin lymphoma. Br J Haematol. 2019 Mar; 184(6):1061–1064.
   PubMed Web of Science ®Google Scholar
• Frydecka I, Mazur G, Kuliczkowski K. Decreased production of interferon gamma by anti-CD3 monoclonal antibody and interleukin-2-stimulated peripheral blood mononuclear cells in hodgkin’s disease. Br J Haematol. 1995 Nov; 91(3):671–673.
   PubMed Web of Science ®Google Scholar
• Sharon E, Streicher H, Goncalves P. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33(9):434–444.
   PubMedGoogle Scholar
• Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct; 7(5):682–686.
   PubMed Web of Science ®Google Scholar
• Callahan GN, Leach DR. Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells. Cancer Detect Prev. 1996;20(3):199–206.
   PubMedGoogle Scholar
• Dranoff G, Jaffee E, Lazenby A. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3539–3543.
   PubMed Web of Science ®Google Scholar
• Black M, Barsoum IB, Truesdell P. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. 2016 Mar 1; 7(9):10557–10567.
   PubMedGoogle Scholar
• Blank C, Kuball J, Voelkl S. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 2006 07 15; 119(2):317–327.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020 Mar 20;123. DOI:10.3390/cancers12030738.
   Web of Science ®Google Scholar
• Reynoso ED, Elpek KG, Francisco L. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009 Feb 15; 182(4):2102–2112.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016 Nov 1; 34(31):3733–3739.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M. Nivolumab for classical hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• Murray PG, Constandinou CM, Crocker J. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in epstein-barr virus-positive hodgkin’s disease. Blood. 1998 Oct 1; 92(7):2477–2483.
   PubMed Web of Science ®Google Scholar
• Reinke S, Bröckelmann PJ, Iaccarino I. Tumor and microenvironment response but no cytotoxic T-cell activation in classic hodgkin lymphoma treated with anti-PD1. Blood. 2020;136(25):2851–2863.
   PubMed Web of Science ®Google Scholar
• Cader FZ, Hu X, Goh WL. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical hodgkin lymphoma. Nat Med. 2020 Sep; 26(9):1468–1479.
   PubMed Web of Science ®Google Scholar
• Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018 Sep; 62:29–39. .
   PubMed Web of Science ®Google Scholar
• Maruyama D, Hatake K, Kinoshita T. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical hodgkin lymphoma. Cancer Sci. 2017 May; 108(5):1007–1012.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Horowitz S. Patients with classical hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 Jul; 27(7):1317–1323.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Nivolumab in the treatment of hodgkin lymphoma. Clin Cancer Res. 2017 Apr 1; 23(7):1623–1626.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial. J Clin Oncol. 2018 May 10; 36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S. Donor leukocyte infusions in recurrent hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. anderson cancer center. Leuk Lymphoma. 20122012/06; 53(6):1239–1241.
   PubMed Web of Science ®Google Scholar
• Herbaux C, Gauthier J, Brice P. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed hodgkin lymphoma. Blood. 2017 May 4; 129(18):2471–2478.
   PubMed Web of Science ®Google Scholar
• Dada RA-O, Usman B Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety. (1600-0609 (Electronic)).
   Google Scholar
• Merryman RW, Castagna L, Corradini P. Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade for classical hodgkin lymphoma: analysis of a large international cohort. Blood. 2019;134(Supplement_1):775.
   Google Scholar
• Scott LJ. Brentuximab vedotin: a review in CD30-positive hodgkin lymphoma. Drugs. 2017 Mar; 77(4):435–445.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, David K. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Hematol Oncol. 2017;35(S2):84–85.
   PubMedGoogle Scholar
• Younes A, Gopal AK, Smith SE. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20; 30(18):2183–2189. .
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma. Blood. 2018 Mar 15; 131(11):1183–1194. .
   PubMed Web of Science ®Google Scholar
• Kaldor JM, Day NE, Clarke EA. Leukemia following hodgkin’s disease. New Engl J Med. 1990 1990 01 04; 322(1):7–13. .
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Advani RH, Bartlett NL. Brentuximab vedotin and nivolumab for relapsed or refractory classic hodgkin lymphoma: long-term follow-up results from the single-arm phase 1/2 study. Blood. 2019;134(Supplement_1):238.
   Google Scholar
• Herrera AF, Chen RW, Palmer J. PET-adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory hodgkin lymphoma. Blood. 2019;134(Supplement_1):239.
   PubMedGoogle Scholar
• Ramchandren R, Domingo-Domènech E, Rueda A. Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol. 20192019 08 10; 37(23):1997–2007.
   PubMed Web of Science ®Google Scholar
• Brockelmann PJ, Goergen H, Keller U. Efficacy of nivolumab and AVD in early-stage unfavorable classic hodgkin lymphoma: the randomized phase 2 german Hodgkin study group NIVAHL trial. JAMA Oncol. 2020 Apr 30;(6). DOI:10.1001/jamaoncol.2020.0750.
   Web of Science ®Google Scholar
• Herrera AF 2969 SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical hodgkin lymphoma. Session: 624. Hodgkin lymphoma and T/NK cell lymphoma—clinical studies: Poster III. Poster session presented at: the 62nd ASH annual meeting and exposition, 2020 Dec 5; CA: San Diego.
   Google Scholar
• Davis KL, Fox E, Merchant MS. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 Apr;21(4):541–550.
   PubMed Web of Science ®Google Scholar
• Harker-Murray P, Leblanc T, Mascarin M. Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed/refractory classical hodgkin lymphoma. Blood. 2018;132(Supplement 1):927.
   Google Scholar
• Yasenchak CA, Bordoni R, Yazbeck V. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with hodgkin lymphoma aged ≥60 years. Blood. 2019;134(Supplement_1):237.
   Google Scholar
• Tonialini L, Stefoni V, Re A. A phase II study of brentuximab vedotin (BV) in the treatment of elderly hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease — FIL_BVHD01. Blood. 2018;132(Supplement 1):2920.
   Google Scholar
• Longley J, Johnson PWM. Options for first line therapy of hodgkin lymphoma. Hematol Oncol. 2019 Jun; 37 Suppl 1(Suppl S1):82–86. .
   PubMedGoogle Scholar
• Armand P, Kuruvilla J, Michot J-M. KEYNOTE-013 4-year follow-up of pembrolizumab in classical hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622.
   PubMed Web of Science ®Google Scholar
• Armand P, Chen YB, Redd RA. PD-1 blockade with pembrolizumab for classical hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 Jul 4; 134(1):22–29.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A. Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (pts) with relapsed/refractory classical hodgkin lymphoma (r/r cHL): exploratory analysis of the randomized, phase 3 keynote-204 study by prior lines of therapy. Blood. 2020;136(Supplement 1):12.
   Google Scholar
• Chen R, Zinzani PL, Fanale MA. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma. J Clin Oncol. 20172017 07 01;35(19):2125–2132.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ. Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 20192019/10; 134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Chen L, Popplewell LL. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and hodgkin lymphoma. Blood. 2019;134(Supplement_1):759.
   Web of Science ®Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory hodgkin lymphoma. Blood. 2020;136(21):2401–2409.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical hodgkin lymphoma. Session: 624. Hodgkin lymphoma and T/NK cell lymphoma—clinical studies: clinical studies in Hodgkin lymphoma. Paper presented at: the 62nd ASH annual meeting and exposition, 2020 Dec 5; CA: San Diego.
   Google Scholar
• Allen PB, Savas H, Evens AM. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical hodgkin lymphoma. Blood.
   Web of Science ®Google Scholar
• Wang J, Fei K, Jing H. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec; 11(8):1443–1451.
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y. Safety and activity of sintilimab in patients with relapsed or refractory classical hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 20192019/01; 6(1):e12–e19.
   PubMed Web of Science ®Google Scholar
• Zhang T, Song X, Xu L. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol Immunother. 2018 Jul; 67(7):1079–1090.
   PubMed Web of Science ®Google Scholar
• Song Y, Gao Q, Zhang H. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. (1476-5551 (Electronic)).
   Google Scholar
• Lee A, Keam SJ. Tislelizumab: first approval. Drugs. 20202020 04 01; 80(6):617–624.
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Chen X. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma. Clin Cancer Res. 2019 Dec 15; 25(24):7363–7369.
   PubMed Web of Science ®Google Scholar
• Nie J, Wang C, Liu Y. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical hodgkin lymphoma. J Clin Oncol. 2019 Jun 10; 37(17):1479–1489.
   PubMed Web of Science ®Google Scholar
• Chen R, Gibb AL, Collins GP. Blockade of the PD-1 checkpoint with anti–PD-L1 antibody avelumab is sufficient for clinical activity in relapsed/refractory classical hodgkin lymphoma (cHL). Hematol Oncol. 2017 2017 06 01; 35(S2):67.
   PubMedGoogle Scholar
• Tivol EA, Borriello F, Schweitzer AN. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995 Nov; 3(5):541–547.
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Yu TF, Leach DR. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):10067–10071.
   PubMed Web of Science ®Google Scholar
• Bashey A, Medina B, Corringham S. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581–1588.
   PubMed Web of Science ®Google Scholar
• Sakamuri D, Glitza IC, Betancourt Cuellar SL. Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther. 2018 Mar; 17(3):671–676.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660–e670.
   PubMed Web of Science ®Google Scholar
• Lang D, Wahl G, Poier N. Impact of PET/CT for assessing response to immunotherapy-a clinical perspective. J Clin Med. 2020 Oct 28;911. DOI:10.3390/jcm9113483.
   Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Mokrane FZ, Chen A, Schwartz LH. Performance of CT compared with (18)F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory hodgkin lymphoma. Radiology. 2020 Jun; 295(3):651–661.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201.
   PubMed Web of Science ®Google Scholar
• Chen L, Diao L, Yang Y. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018 Sep; 8(9):1156–1175.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Pruneri G. Optimizing checkpoint inhibitors therapy for relapsed or progressive classic hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. Cancer Med. 2019;8(6):3012–3016.
   PubMed Web of Science ®Google Scholar
• Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015 2015 01 01; 25(1):28–33. .
   PubMed Web of Science ®Google Scholar
• Michot JM, Mazeron R, Dercle L. Abscopal effect in a hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer. 2016 Oct; 66:91–94. .
   PubMed Web of Science ®Google Scholar
• NCT04419441. [cited 2020 Jun 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04419441?term=nivolumab&cond=Classical+Hodgkin+Lymphoma&draw=3&rank=24
   Google Scholar
• NCT03480334. [cited 2018 Mar 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03480334?term=nivolumab&cond=Classical+Hodgkin+Lymphoma&draw=2&rank=5
   Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011 Mar; 8(3):151–160.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S, Garrigós C, Duran I Biomarkers of response to PD-1/PD-L1 inhibition. (1879-0461 (Electronic)).
   Google Scholar
• Shi Y, Su H, Song Y. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine. 2020 Apr; 54:102731.
   PubMed Web of Science ®Google Scholar
• Oweida A, Hararah MK, Phan A. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. (1078-0432 (Print)).
   Google Scholar
• Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–1911.
   PubMed Web of Science ®Google Scholar